Merck于2026年1月7日完成Cidara治疗器的购置,以扩大其抗芬格尔药物管道。 Merck completes acquisition of Cidara Therapeutics on January 7, 2026, to expand its antifungal drug pipeline.

Merck在2026年1月7日(星期三)完成交易, Merck has finalized its acquisition of Cidara Therapeutics, completing the deal on Wednesday, January 7, 2026. 此举扩大了默克在抗真菌治疗领域的产品组合，将Cidara的研发流程和技术整合进其药物开发工作中。 The move expands Merck’s portfolio in antifungal therapies, integrating Cidara’s pipeline and technology into its pharmaceutical development efforts. 收购加强了Merck在传染病治疗中的地位,特别是在医疗需求不断增长的地区。 The acquisition strengthens Merck’s position in infectious disease treatments, particularly in areas with growing medical need.